BioSante Pharmaceuticals, Inc. to Present at Cancer Immunotherapy Conference

Printer-friendly versionPDF version

LINCOLNSHIRE, Illinois (October 3, 2011)– BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.

Stephen M. Simes, BioSante's president & chief executive officer, will speak at 1:45 pm EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials.

The conference will be hosted by MD Becker Partners and sponsored by JMP Securities, Thompson Hine, Roth Capital Partners and Cantor Fitzgerald. There will be a corresponding live webcast of the presentations, which can be accessed by visitingwww.regonline.com/mdbpartners. A replay will be available for 30 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel^®(transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin (estradiol gel), indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at:www.biosantepharma.com.

About MD Becker Partners

MD Becker Partners LLC is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. As a strategic advisor and partner, the firm provides a full range of services to help clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, MD Becker Partners integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visitwww.mdbpartners.com.

###

For more information please contact:

For Media:
Alan Zachary
Harris D. McKinney
(312) 506-5220

azachary@harrisdmckinney.com

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953

tswanson@troutgroup.com

News Source : BioSante Pharmaceuticals, Inc. to Present at Cancer Immunotherapy Conference